On Friday, Prelude Therapeutics Inc (NASDAQ: PRLD) opened lower -7.63% from the last session, before settling in for the closing price of $1.31. Price fluctuations for PRLD have ranged from $0.61 to $5.53 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -21.61% over the past five years. Company’s average yearly earnings per share was noted 20.44% at the time writing. With a float of $24.42 million, this company’s outstanding shares have now reached $43.74 million.
Prelude Therapeutics Inc (PRLD) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Prelude Therapeutics Inc is 56.86%, while institutional ownership is 28.82%. The most recent insider transaction that took place on Mar 25 ’25, was worth 69,250. In this transaction Chief Chemistry Officer of this company bought 100,000 shares at a rate of $0.69, taking the stock ownership to the 480,123 shares. Before that another transaction happened on Mar 25 ’25, when Company’s CEO bought 675,000 for $0.69, making the entire transaction worth $467,438. This insider now owns 1,999,296 shares in total.
Prelude Therapeutics Inc (PRLD) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.43 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.46) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.44% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.45% during the next five years compared to -21.61% drop over the previous five years of trading.
Prelude Therapeutics Inc (NASDAQ: PRLD) Trading Performance Indicators
Check out the current performance indicators for Prelude Therapeutics Inc (PRLD). In the past quarter, the stock posted a quick ratio of 3.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.78, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -0.86 in one year’s time.
Technical Analysis of Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc (NASDAQ: PRLD) saw its 5-day average volume 0.34 million, a positive change from its year-to-date volume of 0.2 million. As of the previous 9 days, the stock’s Stochastic %D was 88.89%.
During the past 100 days, Prelude Therapeutics Inc’s (PRLD) raw stochastic average was set at 83.33%, which indicates a significant increase from 79.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1522 in the past 14 days, which was higher than the 0.0959 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9060, while its 200-day Moving Average is $0.9269. Nevertheless, the first resistance level for the watch stands at $1.2833 in the near term. At $1.3566, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.4132. If the price goes on to break the first support level at $1.1534, it is likely to go to the next support level at $1.0968. Assuming the price breaks the second support level, the third support level stands at $1.0235.
Prelude Therapeutics Inc (NASDAQ: PRLD) Key Stats
There are currently 56,600K shares outstanding in the company with a market cap of 68.48 million. Presently, the company’s annual sales total 7,000 K according to its annual income of -127,170 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -32,090 K.
